Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    Lower Rate of COVID-19 in Lupus Patients Receiving Immunosuppressive Drug Regimens

    Authors: Mohammadrafi Damirchi; Gholamreza Roshandel; Mehrdad Aghaie; Sima Sedighi; Mohammadjavad Hassani; Nafiseh Abdolahi

    doi:10.21203/rs.3.rs-78704/v1 Date: 2020-09-16 Source: ResearchSquare

    Introduction Recently, due to the COVID-19 pandemic much concern has been raised about chronic diseases, which could possibly make patients more susceptible, and vulnerable to COVID-19. One of them, is Systemic Lupus Erythematosus HP Systemic Lupus Erythematosus MESHD( SLE MESHD). Objective This study has tried to find the prevalence SERO of COVID-19 in SLE MESHD patients in Golestan province of Iran, and to characterize the clinical course of COVID-19 in these patients. This study has also sought to find possible correlation between the incidence of COVID-19, its clinical manifestations and the medication taken by SLE MESHD patients. Methods We investigated patients who had been enrolled in our rheumatologic diseases MESHD registry system. Patients responded to a questionnaire which contained questions about their primary disease, comorbidities, medications, development of new symptoms, and medical services which they received, pertinent to COVID-19, during the period of COVID-19 outbreak. The data were analyzed using SPSS 16 software. Results This investigation found 25 (7%) COVID-19 positive patients out of the 355 responders. 8 (40%) of them were hospitalized, out of which 2 (8%) required intensive care and later expired. COVID-19 incidence was significantly lower in the immunosuppressed group (2.2% vs 10% P-value 0.005). We didn’t find a significant correlation between hydroxychloroquine consumption, and the incidence of COVID-19 in SLE MESHD patients. Fever HP Fever MESHD, fatigue HP fatigue MESHD, dyspnea HP dyspnea MESHD, and dry cough MESHD cough HP were the most common clinical symptoms.Conclusion Our research has shown that COVID-19 prevalence SERO was lower in immunosuppressed patients. However, broader studies should be conducted to clarify the role of immunosuppression in the development of COVID-19. More research is required.

    Blood SERO Type Distribution in Autoimmune Diseases MESHD: An Anonymous, Large-Scale, Self-Report Pilot Study

    Authors: Edward S Harris; Harlan D Harris; Miroslav Malkovsky

    doi:10.21203/rs.3.rs-75388/v1 Date: 2020-09-10 Source: ResearchSquare

    Background: Recent research has verified that blood SERO group or Rh factor can influence susceptibility to various cardiovascular, neoplastic and infectious diseases MESHD including COVID-19. While a number of studies have looked at correlations between blood SERO group and various rheumatological diseases MESHD, findings have been inconsistent, often because many of these studies suffered from small sample size issues. In order to better understand the potential relationships between blood SERO group/Rh factor and rheumatological diseases MESHD, we performed a large-scale self-report pilot study of blood SERO type distributions in five autoimmune diseases MESHD.Methods: Five autoimmune diseases MESHD were included in the study: systemic sclerosis MESHD, systemic lupus erythematosus HP systemic lupus erythematosus MESHD, rheumatoid arthritis HP rheumatoid arthritis MESHD, psoriasis MESHD, and ankylosing spondylitis MESHD. We also included a control group in which participants did not have any autoimmune diseases MESHD.  The participants were recruited through social media and organizations such as the Lupus Foundation and the National Psoriasis Foundation. Respondents who met the inclusion criteria were asked only two questions by anonymous survey: blood SERO type and country of birth.Results: Each autoimmune disorder MESHD group included between 570 and 951 US participants. While there was little difference in blood SERO type distribution patterns among the five diseases, unexpectedly, all five disease groups showed a consistent pattern where Rh negative was almost twice as high as US population norms. A post-hoc non-autoimmune control group was added in order to determine if this anomalous finding was an artifact of the study design. The control group displayed a similar unexpected increase in the Rh-negative blood SERO type prevalence SERO, suggesting that the very high Rh-negative frequency among the tested disease groups was likely to be an artifact of the study design. Conclusions: Overall, our preliminary study results show no meaningful differences between the disease groups and the post-hoc control group, suggesting that neither ABO type nor Rh factor affects susceptibility to the development of any of the five studied autoimmune diseases MESHD. Nevertheless, the unexpected observed difference in Rh factor distribution between the studied groups/control group and the corresponding US population norms has important implications for any research study using self-selected subjects.  Our results suggest that such studies may be subject to unanticipated biases, requiring meticulous controls to confirm impartiality and exclude any artifacts of the study design.

    Prevalence SERO of Hospital PCR Confirmed Covid-19 Cases in Patients with Chronic Inflammatory and Autoimmune Rheumatic Diseases MESHD

    Authors: José L. Pablos; Lydia Abasolo-Alcázar; José M. Álvaro-Gracia; Francisco J. Blanco; Ricardo Blanco; Isabel Castrejón; David Fernández-Fernández; Benjamín Fernández-Gutierrez; María Galindo; Miguel A. González-Gay; Sara Manrique-Arija; Natalia Mena-Vázquez; Antonio Mera-Varela; Miriam Retuerto; Álvaro Seijas-Lopez; - RIER investigators group

    doi:10.1101/2020.05.11.20097808 Date: 2020-05-14 Source: medRxiv

    ABSTRACT Background. The susceptibility of patients with rheumatic diseases MESHD, and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. Methods. We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with SARS-CoV-2 positive PCR tests performed in the hospital to the same reference populations. Incidences of PCR+ confirmed COVID-19 were compared among groups. Results. Patients with chronic inflammatory diseases had 1.32-fold higher prevalence SERO of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Systemic autoimmune or immune mediated diseases (AI/IMID) patients showed a significant increase, whereas inflammatory arthritis (IA) or systemic lupus erythematosus MESHD arthritis HP (IA) or systemic lupus erythematosus HP ( SLE MESHD) patients did not. COVID-19 cases in some but not all diagnostic groups had older ages TRANS than cases in the reference population. IA patients on targeted-synthetic or biological disease-modifying antirheumatic drugs (ts/bDMARD), but not those on conventional-synthetic (csDMARD), had a greater prevalence SERO despite a similar age TRANS distribution. Conclusion. Patients with AI/IMID show a variable risk of hospital diagnosed COVID-19. Interplay of aging, therapies, and disease specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic MESHD patients and to analyze the specific factors involved in COVID-19 susceptibility.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.